U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE **FORM PTO-1449** 

ZL

Rb

Ph

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET: 17243CIP3(AP)	SERIAL NO.: 08/815,362
APPLICANT: Chow et al	METHOD OF TREATMENT WITH COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON ALPHA 2B AND/OR 2C
FILING DATE: March 21, 2001	GROUP: Not Known 16 26

**U.S. PATENT DOCUMENTS** FILING DATE SUB-CLASS NAME **CLASS** \*EXAMINER DATE DOCUMENT NO. (if applicable) Gluchowski 12/31/1991 AA 5,077,292 7/23/1991 Gluchowski 5,034,406 AB Gluchowski 6/4/1991 AC 5,021,416 Rh Głuchowski 7/14/1992 AD 5,130,441 Gluchowski 11/19/1991 es 5,066,664 ΑE Gluchowski 9/29/1992 AF H 5,151,440 Gluchowski 5/12/1992 Ph AG 5,112,822 2/25/1992 Gluchowski R 5.091,528 AH RL 7/27/1993 Gluchowski ΑI 5,231,096 Gluchowski AJ 3/30/1993 5,198,442 12/3/1996 Garst et al AK 5,580,892 9/3/1996 Burke et al Ch 5,552,403 AL 9/2/1997 Maurer et al 从 5,663,189 **AM** 6/1/1993 Burke et al AN 5,215,991 B 1/19/1993 Burke et al 5,180,721 从 AO R Burke et al AP 10/1/1996 5,561,132 4/15/1997 Boyd et al AQ 5,621,113 397 Karjalainen et al AR RE 32,400 4/1987 从 R 4/1984 Karjalainen et al **AS** 4,443,466 Cross et al 1/1985 RA **AT** 337 4,496,572 9/1985 AU Bailey 40 4,540,705 548 3/51/X Ā۷ 9/1992 5,151,526 Hsu et al PG TOH 5,750,720 548 AW 5/1998 Boyd et al II

DATE CONSIDERED EXAMINER To \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Lebessa Ander

1/13/04

Sheet 2 of 3

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE **FORM PTO-1449** 

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET: 17243CIP3(AP)	SERIAL NO.: 09/815,362		
APPLICANT:	07/010,002		
Chow et al	METHOD OF TREATMENT WITH COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON ALPHA 2B AND/OR 2C		
FILING DATE:	GROUP:		
March 21, 2001	Net Known 1626		

FOREIGN PATENT DOCUMENTS

16		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
1014	AX	0 194 984	9/17/1986	EPO	4		
1	AY	0 304 910	3/1/1989	EPO			
	BB	WO 97/35858	10/2/1997	WIPU-PCT			
	BC	WO 97/31636	9/4/1997	WIRD PCT			
	BD	WO 95/19968	7/27/1995	EUIPO PET			
	BE	WO 97/03079	1/30/1997	WIFO PCT			
	BF	WO 97/15302	5/1/1997	WIFE PET			
	BG	WO 95/16449	6/22/1995	WIPD BET	,		
	ВН	WO 97/12874		WIPO PCT ORIGO	, ,		
	BI	WO 94/07866 -	4/14/1994	WIRD PET LONG			
1	BJ	WO 96/01813	1/15/1996	WIFU PCF		1	
V	BK	1/242571	9/1989	JAPAN CTHAR	A	ユー	
THE	BL	4/267130	1992	JAPAN			

DATE CONSIDERED 09-18-2001

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1/13/04



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE **FORM PTO-1449** 

Sheet 3 of 3

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	· · · · · · · · · · · · · · · · · · ·
ATTY. DOCKET:	SERIAL NO.:
17243CIP3(AP)	09/815,362
APPLICANT:	
Chow et al	METHOD OF TREATMENT WITH COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON ALPHA 2B AND/OR 2C
FILING DATE:	GROUP:
March 21, 2001	Not Known 1626

OTHER PRIOR ART

		(Including Author, Title, Date, Pertinent Pages, etc.)
PL	BM BM	Bylund et al, 1994, Pharmacol Rev. 46, pp. 121-136, "International Union of
F- 0	11/18	Pharmacology Nomenclature of Adrenoceptors"
4.	BN	Shimizu et al, 1969, J. Neurochem. 16, pages 1609-1619, "A Radiosotopic Method
H		For Measuring The Formation of Adenosine 3', 5'-Cyclic Monophosphate in
		Incubated Slices Of Brain"
RA	ВО	Messier et al, 1995, Pharmacol. Toxicol. 76, pages 308-311, "High Throughput
KA		Assays of Cloned Adrenergic, Muscarinic, Neurokinin, and Neurotrophin
		Receptors in Living Mammalian Cells"
	BP	Neve et al, 1992, J. Biol. Chem. 267, pages 25748-25753, "Dopamine D2 Receptor
PL		Stimulation of Na+/H+ Exchange Assessed by Quantification of Extracellular
		Acidification"
B	BQ	Williams et al, 1990, J. Auton. Pharmacol, 10, 247, pages 109-118, "α 2-
1 ,		adrenoceptor antisecretory responses in the rat jejunum"
4	BR	Fondacaro et al, 1988, Vol. 247, No. 2, pages 481-486, "The Journal of
$\mathcal{N}$		Pharmacology and Experimental Therapeutics"
PL	BS	White et al, 1975, Communications/Synthesis, pages 602-3, "A Convenient
		Procedure for the Preparation of 2-endo-Hydroxy-cis-bicyclo [3.3.0]octane"
%	BT	Conklin et al, Nature, 1993, Vol. 363, pages 274-6, "Substitution of three amino
, •		acids switches receptor specifity of $G_{\alpha}$ to that of $G_{1}\alpha$ "
Rb	BU	Schaaf et al, J. Med. Chem. 1983, Vol. 26, pages 328-334, "Structure-Activity
Ī		Studies of Configurationally Rigid Arylprostaglandins"
lb 1	BV	Kihara et al, "Preparation of imidazole derivatives as drugs", 6001 Chemical
, - 0	V	Abstracts, Columbus, Ohio, U.S. Vol. 112 (4/9/1996), No. 16, XP-002098179
	BW	Zhang et al, "Medetomidine Analogs as α <sub>2</sub> -Adrenergic Ligands. 3. Synthesis
丛		and Biological Evaluation of a New Series of Medetomidine Analogs and Their
	WIT	Potential Binding Interactions with α2-Adrenoceptors Involving a 'Methyl
		Pocket' ", J. Med. Chemc. 1997, 40. pgs. 3014-3024
	EXAMINED 2	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Leleur Anders

1113/04